{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T03:04:30Z","timestamp":1776913470827,"version":"3.51.2"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":129,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dieter Morszeck Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pulmonary fibrosis is a rare, but dangerous side effect of CCNU (lomustine). CCNU is a frequently used chemotherapeutic agent in the setting of recurrent or progressive glioblastoma. At present, CCNU is also administered in patients with newly diagnosed gliomas in combination with temozolomide. There is only little evidence if, and how, lung function should be monitored on treatment with CCNU.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively collected data on patient characteristics, lung function analyses, and relevant toxicities among 166 brain tumor patients treated with CCNU at a German University Hospital and National Cancer Center.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The patient collective mainly included patients with recurrent glioblastoma who received a mean number of 2.64 \u00b1 1.57 cycles. There was overall no statistically significant change in parameters of pulmonary restriction among patients treated with CCNU. On an individual patient basis, a &amp;gt;10% decrease in the absolute vital capacity was primarily seen in patients with prior lung diseases and smokers. Other severe toxicities mainly included thrombocytopenia, leukopenia, nausea, and vomiting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our findings support to limit lung function analyses on CCNU to patients with gliomas and pulmonary risk factors. However, all patients should be closely followed for clinical symptoms of pulmonary restriction.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdac068","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T21:20:47Z","timestamp":1652217647000},"source":"Crossref","is-referenced-by-count":7,"title":["Lung toxicity of lomustine in the treatment of progressive gliomas"],"prefix":"10.1093","volume":"4","author":[{"given":"Corinna","family":"Seliger","sequence":"first","affiliation":[{"name":"Department of Neurology and National Center for Tumor Diseases, University Hospital Heidelberg , Heidelberg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"N\u00fcrnberg","sequence":"additional","affiliation":[{"name":"Department of Neurology and National Center for Tumor Diseases, University Hospital Heidelberg , Heidelberg , Germany"},{"name":"Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-634X","authenticated-orcid":false,"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[{"name":"Department of Neurology and National Center for Tumor Diseases, University Hospital Heidelberg , Heidelberg , Germany"},{"name":"Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Wick","sequence":"additional","affiliation":[{"name":"Department of Neurology and National Center for Tumor Diseases, University Hospital Heidelberg , Heidelberg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"2022053121153745900_CIT0001","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013\u20132017","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro Oncol."},{"issue":"8","key":"2022053121153745900_CIT0002","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"issue":"3","key":"2022053121153745900_CIT0003","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"key":"2022053121153745900_CIT0004","doi-asserted-by":"crossref","first-page":"e000520","DOI":"10.1136\/esmoopen-2019-000520","article-title":"How we treat glioblastoma","volume":"4","author":"Weller","year":"2019","journal-title":"ESMO Open."},{"issue":"10","key":"2022053121153745900_CIT0005","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"3","key":"2022053121153745900_CIT0006","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402","volume":"31","author":"Cairncross","year":"2013","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022053121153745900_CIT0007","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951","volume":"31","author":"van den Bent","year":"2013","journal-title":"J Clin Oncol."},{"issue":"14","key":"2022053121153745900_CIT0008","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med."},{"key":"2022053121153745900_CIT0009","doi-asserted-by":"crossref","first-page":"102029","DOI":"10.1016\/j.ctrv.2020.102029","article-title":"How did lomustine become standard of care in recurrent glioblastoma?","volume":"87","author":"Weller","year":"2020","journal-title":"Cancer Treat Rev."},{"issue":"10172","key":"2022053121153745900_CIT0010","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet."},{"issue":"2","key":"2022053121153745900_CIT0011","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2003.06.023","article-title":"Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities","volume":"21","author":"Buckner","year":"2003","journal-title":"J Clin Oncol."},{"issue":"17","key":"2022053121153745900_CIT0012","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1200\/JCO.2003.03.509","article-title":"Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma","volume":"21","author":"Weller","year":"2003","journal-title":"J Clin Oncol."},{"key":"2022053121153745900_CIT0013"},{"key":"2022053121153745900_CIT0014"},{"issue":"3","key":"2022053121153745900_CIT0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/mpo.2950060310","article-title":"Pulmonary toxicity from carmustine (BCNU): a case report","volume":"6","author":"Weiss","year":"1979","journal-title":"Med Pediatr Oncol."},{"issue":"11","key":"2022053121153745900_CIT0016","first-page":"1691","article-title":"Pulmonary toxicity in long-term administration of BCNU","volume":"60","author":"Holoye","year":"1976","journal-title":"Cancer Treat Rep."},{"issue":"3","key":"2022053121153745900_CIT0017","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1378\/chest.72.3.372","article-title":"Pulmonary fibrosis after prolonged therapy with 1,3-bis (2-chloroethyl)-1-nitrosourea","volume":"72","author":"Crittenden","year":"1977","journal-title":"Chest."},{"issue":"1","key":"2022053121153745900_CIT0018","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/1097-0142(197807)42:1<74::AID-CNCR2820420111>3.0.CO;2-I","article-title":"Fatal pulmonary fibrosis following 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy","volume":"42","author":"Bailey","year":"1978","journal-title":"Cancer."},{"issue":"1","key":"2022053121153745900_CIT0019","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00000441-198001000-00007","article-title":"Irreversible pulmonary toxicity after single course of BCNU","volume":"279","author":"Lieberman","year":"1980","journal-title":"Am J Med Sci."},{"issue":"4","key":"2022053121153745900_CIT0020","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/0002-9343(77)90424-7","article-title":"Cytotoxic drug-induced lung disease","volume":"62","author":"Sostman","year":"1977","journal-title":"Am J Med."},{"key":"2022053121153745900_CIT0021"},{"issue":"1","key":"2022053121153745900_CIT0022","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12885-016-2131-6","article-title":"Chemotherapy with BCNU in recurrent glioma: analysis of clinical outcome and side effects in chemotherapy-naive patients","volume":"16","author":"Jungk","year":"2016","journal-title":"BMC Cancer."},{"issue":"11","key":"2022053121153745900_CIT0023","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/cncr.10978","article-title":"Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study","volume":"95","author":"Mertens","year":"2002","journal-title":"Cancer."},{"issue":"10","key":"2022053121153745900_CIT0024","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1023\/A:1008287922285","article-title":"Long-term survivors of small-cell lung cancer (SCLC): a French multicenter study. Groupe d\u2019Oncologie de Langue Francaise","volume":"8","author":"Jacoulet","year":"1997","journal-title":"Ann Oncol."},{"issue":"6","key":"2022053121153745900_CIT0025","first-page":"731","article-title":"[High dose ACNU and radiation therapy with autologous bone marrow rescue for a patient with cerebellar medulloblastoma: case report]","volume":"12","author":"Matsumoto","year":"1984","journal-title":"No Shinkei Geka."},{"issue":"6","key":"2022053121153745900_CIT0026","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJM199008093230604","article-title":"Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood","volume":"323","author":"O\u2019Driscoll","year":"1990","journal-title":"N Engl J Med."},{"issue":"4","key":"2022053121153745900_CIT0027","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annder.2011.12.034","article-title":"[New toxicity of fotemustine: diffuse interstitial lung disease]","volume":"139","author":"Bertrand","year":"2012","journal-title":"Ann Dermatol Venereol."},{"issue":"1","key":"2022053121153745900_CIT0028","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/030089168607200114","article-title":"Lomustine (CCNU)-induced pulmonary fibrosis","volume":"72","author":"Tucci","year":"1986","journal-title":"Tumori."},{"issue":"6","key":"2022053121153745900_CIT0029","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10637-005-1761-3","article-title":"Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"23","author":"Webster","year":"2005","journal-title":"Invest New Drugs."},{"key":"2022053121153745900_CIT0030"},{"issue":"26","key":"2022053121153745900_CIT0031","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma","volume":"31","author":"Batchelor","year":"2013","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022053121153745900_CIT0032","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","article-title":"Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial","volume":"15","author":"Taal","year":"2014","journal-title":"Lancet Oncol."},{"issue":"5","key":"2022053121153745900_CIT0033","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/neuonc\/noz222","article-title":"INTELLANCE 2\/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma","volume":"22","author":"Van Den Bent","year":"2020","journal-title":"Neuro Oncol."},{"issue":"18","key":"2022053121153745900_CIT0034","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1200\/JCO.2005.04.3414","article-title":"Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402","volume":"24","author":"Intergroup Radiation Therapy Oncology Group Trial 9402","year":"2006","journal-title":"J Clin Oncol."},{"issue":"18","key":"2022053121153745900_CIT0035","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1200\/JCO.2005.04.6078","article-title":"Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial","volume":"24","author":"van den Bent","year":"2006","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022053121153745900_CIT0036","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12885-021-07809-5","article-title":"One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a National Neuro-oncology Centre","volume":"21","author":"Keogh","year":"2021","journal-title":"BMC Cancer."},{"issue":"10","key":"2022053121153745900_CIT0037","first-page":"e11070","article-title":"Toxicity profile of procarbazine lomustine and vincristine chemotherapy in low-grade glioma\u2014retrospective review","volume":"12","author":"Irfan","year":"2020","journal-title":"Cureus."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdac068\/43660019\/vdac068.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/4\/1\/vdac068\/43887831\/vdac068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/4\/1\/vdac068\/43887831\/vdac068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T21:16:23Z","timestamp":1654031783000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdac068\/6583451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdac068","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2022,1,1]]},"article-number":"vdac068"}}